Future of <i>Helicobacter pylori</i> Eradication-New Trials

Song, Hyun Joo

doi:2012.12.4.232

Korean J Helicobacter Up Gastrointest Res > Volume 12(4); 2012 > Article

Review

The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2012;12(4):232-236.
DOI: https://doi.org/10.7704/kjhugr.2012.12.4.232 Published online December 10, 2012.

Future of Helicobacter pylori Eradication-New Trials

Hyun Joo Song

Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea. songhj@jejunu.ac.kr

헬리코박터 제균 치료의 현재와 미래-제균 치료의 미래

송현주

제주대학교 의학전문대학원 내과학교실

Abstract

The efficacy of standard 7~14 day triple therapy is decreasing, mainly due to increased primary bacterial resistance to antibiotics. Recent published studies have therefore focused on developing alternative strategies for first-line eradication of Helicobacter pylori. Clear evidence now exists that levofloxacin is a viable option for first-line therapy. In addition, data have emerged that the probiotic Saccharomyces boulardii and Lactobacillus supplementation may be a useful adjunct to antibiotic therapy. Among the novel molecules, benzimidazole-derivatives, polycyclic compounds, pyloricidin, and arylthiazole analogues seem to be the most promising. The sequential and 'concomitant' regimes have also been studied in new settings and may have a role in future algorithms. Other studies promote individualized therapies based on host polymorphisms, age, and other demographic factors and resistance. In the near future, tailored therapy could optimize eradication regimens within the different countries. This article reviews the literature published pertaining to new clinical trials of H. pylori eradication.

Key Words: Helicobacter pylori; Clinical trial